


Magazine Announces the Research and Development 250 and 251+ Lists Featuring Companies with the Highest R&D Expenditures in 2022. TriaTech Entered the List at the 363rd Position.

The results of the Turkey R&D 250 research have been unveiled, identifying companies that achieved significant success in the field of research and development in 2022, providing a valuable reference both domestically and internationally. This year, the top 500 companies with the highest R&D expenditures have been disclosed and curated into a prestigious list. The Turkey R&D 250 research is based on the data from the top 500 companies in Turkey's export rankings, firms that share their R&D data on the Public Disclosure Platform, and surveys conducted by R&D centers approved by the Ministry of Industry and Technology of the Republic of Turkey.

The core data for the Turkey R&D 250 research comprises R&D expenditures in 2022 and their proportion to total revenues, planned R&D expenditures for 2023, R&D personnel counts, the number of patents, utility models, design registrations, and trademarks obtained in R&D centers in 2022, as well as the ratio of R&D support acquired in 2022.

TriaTech Tibbi Sistemler San. ve Tic. A.Ş., based in Izmir/Turkey and renowned for its investments in the STOCKART Automated Medication and Supply Management Systems brand, has made a significant impact by securing the 363rd position in the "2022 Second 250 Companies with the Highest R&D Expenditures" list. TriaTech is dedicated to producing high-tech, value-added, and competitive products, with a focus on reducing foreign dependence in the medical device sector, boosting employment, and enhancing customer satisfaction and loyalty through a combination of cost advantages and quality approaches. Additionally, TriaTech is committed to executing a global growth strategy to increase the visibility of the STOCKART brand abroad and contribute to positioning Turkey as an attractive hub. In the forthcoming years, they plan to further amplify their investments in research and development to achieve these goals.

Source: <https://turkishtimedergi.com/arqe250/arqe250-500.html>



2022 AR-GE İKİNCİ 250 FİRMA
EN ÇOK AR-GE HARCAMASI YAPAN İKİNCİ 250 FİRMA

| SIRASI | FİRMA ADI | AR-GE HARCAMASI (MİLYAR TL) | AR-GE HARCAMASI / SATIŞ GELİRLERİ (%) | AR-GE PERSONEL SAYISI | AR-GE PROJELERİ SAYISI | AR-GE PLANLANAN HARCAMASI (MİLYAR TL) |
|--------|--|-----------------------------|---------------------------------------|-----------------------|------------------------|---------------------------------------|
| 363 | TriaTech Tibbi Sistemler San. ve Tic. A.Ş. | 9.394.921 | 1,10 | 16 | 8 | 20.000.000 |

EN ÇOK AR-GE HARCAMASI YAPAN İLK 250 – İKİNCİ 250 FİRMA VE KATEGORİLERE GÖRE SIRALAMALAR

TOP 250 – NEXT TOP 250 COMPANIES WITH THE HIGHEST R&D EXPENDITURE AND RANKINGS BY CATEGORIES

| 2022 SIRA RANKING IN 2022 | ŞİRKET COMPANY | 2022 AR-GE HARCAMASI 2022 R&D EXPENSES (TL) | YÜRÜTÜLEN AR-GE PROJE SAYISI NUMBER OF R&D PROJECTS CONDUCTED | AR-GE PERSONEL SAYISI NUMBER OF R&D STAFF | 2023'DE PLANLANAN AR-GE HARCAMASI R&D EXPENSES PLANNED FOR 2023 (TL) |
|---------------------------|--|---|---|---|--|
| 363 | TriaTech Tibbi Sistemler San. ve Tic. A.Ş. | 9.394.921 | 8 | 16 | 20.000.000 |